Lexeo Therapeutics opened lower at $3.02, compared with its previous close of $3.07. In the last trading session, the stock traded between $2.82 and $3.05. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Lexeo Therapeutics is now worth
$ 29.02
Resulting in a loss of
$ 70.98 (70.98%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.15 (-4.98%)
Day High
$3.05
Day Low
$2.82
Day Open
$3.02
Prev Close
$3.07
Volume
15,25,318
1W Return
-10.05%
1M Return
-4.52%
3M Return
-39.05%
6M Return
-52.34%
1Y Return
-68.02%
Fundamentals
Market Cap ($ Mn)
239
PE Ratio
-
PB Ratio
1.63
PEG Ratio
-
ROE
-70.33%
ROCE
-71.36%
EPS (TTM)
$-0.33
Investment Returns
1 Week
-10.05%
1 Month
-4.52%
3 Months
-39.05%
6 Months
-52.34%
9 Months
-57.04%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
22Sep
Lexeo Therapeutics acquires Mantle Therapeutics in $21.3 million deal
Lexeo Therapeutics acquires Mantle Therapeutics for $8.3M upfront plus up to $13.0M in milestones. Deal adds four Friedreich ataxia programs targeting frataxin restoration via oral, recombinant, and ASO mechanisms. Cash runway guidance maintained into 2028 despite acquisition costs. Parallel collaborations announced with Weill Cornell, Vivet Therapeutics, and Apertura Gene Therapy for CNS delivery.
1mo ago
25Jun
JP Morgan keeps overweight on Lexeo, cuts target to $9
JP Morgan analyst Tessa Romero maintained an Overweight rating on Lexeo Therapeutics but lowered the price target to $9 from $12.
4mo ago
18Jun
Lexeo publishes Phase I/II data in JAMA Cardiology
Lexeo Therapeutics has published positive Phase I/II data for its gene therapy candidate LX2006 in JAMA Cardiology, demonstrating early signs of efficacy and a favorable safety profile in patients with Friedreich ataxia. The data, combining results from two independent studies, showed improvements in cardiac biomarkers and frataxin expression. Building on these findings, the company is on track to initiate the pivotal SUNRISE-FA 2 study by the end of June 2026, with topline data expected in the second half of 2027.
